8-K: InfuSystem Reports Q2 2026 Growth, Reaffirms Guidance

InfuSystem Holdings, Inc. announced its second quarter 2026 financial results, showcasing a 2.6% increase in net revenues to $36.9 million and a 7.6% rise in Adjusted EBITDA to $8.6 million, while reaffirming full-year guidance.

Summary

• InfuSystem Holdings, Inc. reported second quarter 2026 net revenues of $36.9 million, a 2.6% increase year-over-year.
• Patient Services net revenue grew by 15% to $24.8 million, driven by Oncology and Wound Care.
• Device Solutions net revenue decreased by 16% to $12.1 million, primarily due to a restructured GE Healthcare contract.
• Gross profit increased by 8% to $21.4 million, with gross margin improving to 58%.
• Net income rose to $3.2 million ($0.15 per diluted share) from $2.6 million ($0.12 per diluted share) in the prior year.
• Adjusted EBITDA (non-GAAP) increased by 8% to $8.6 million, with Adjusted EBITDA margin expanding to 23.4%.
• The company reaffirmed its full-year 2026 pro-forma net revenue growth guidance of 6% to 8% and expects Adjusted EBITDA margins in the mid to low 20%'s.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with revenue growth, margin expansion, and reaffirmed guidance, despite some segment-specific revenue declines.

Positives

• Net revenues increased by 2.6% to $36.9 million in Q2 2026.
• Patient Services segment revenue grew significantly by 15.2% to $24.8 million.
• Wound Care revenue saw exceptional growth of 154% due to new lymphedema compression therapy offerings.
• Gross profit increased by 7.7% to $21.4 million.
• Gross margin improved to 58.0% from 55.2% in the prior year.
• Net income increased to $3.2 million ($0.15 per diluted share) from $2.6 million ($0.12 per diluted share).
• Adjusted EBITDA increased by 7.6% to $8.6 million.
• Adjusted EBITDA margin expanded by 1.1% to 23.4%.
• Full-year 2026 pro-forma net revenue growth guidance of 6% to 8% was reaffirmed.
• Company liquidity totaled $55.2 million as of June 30, 2026.

Negatives

• Device Solutions net revenue decreased by 16.1% to $12.1 million.
• Biomedical services revenue within Device Solutions decreased by 39.4% due to the GE Healthcare contract restructuring.
• Medical equipment sales within Device Solutions decreased by 49.0% due to a large customer rental buyout.
• Operating cash flow for the six-month period decreased by 12% to $7.7 million.
• Net debt increased by $3.0 million to $19.5 million as of June 30, 2026.

Risks

• Risks factors discussed in the most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 27, 2026.
• Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially.
• Uncertain impact of disruptions caused by public health emergencies or extreme weather or other climate change-related events.
• Dependence on estimates of collectible revenue.
• Potential litigation.
• Changes in third-party reimbursement processes.
• Changes in law.
• Global financial conditions and recessionary risks, rising inflation and interest rates, supply chain disruptions, systemic pressures in the banking sector, including disruptions to credit markets.

Future Outlook

The company reaffirms its full-year 2026 pro-forma net revenue growth guidance of 6% to 8% and forecasts Adjusted EBITDA margin (non-GAAP) to be in the mid to low 20%'s, including implementation expenses for upgraded information technology systems.

Management Comments

• "We delivered another strong quarter, achieving record revenue of $36.9 million and growing Adjusted EBITDA by 7.6%."
• "Our Oncology business continued its steady momentum, surpassing $20 million in quarterly revenue for the first time, while Wound Care delivered exceptional growth driven by strong adoption of our new lymphedema compression therapy offerings."
• "As our business continues to diversify, we remain focused on pursuing profitable growth while driving ever greater efficiencies."
• "The previously reported restructuring of our GE Healthcare contract reduced reported revenue in our Device Solutions business unit, but it also improved the Company's profitability through a greater reduction in direct costs. This has resulted in margin expansion and higher reported profits."
• "The rapid growth of our compression therapy business has provided new revenue resources and we believe our payer network, operational capabilities, and manufacturer partnerships position us well for continued expansion."
• "Behind the scenes, we made meaningful progress optimizing our new ERP platform, laying the foundation for greater scalability, efficiency, and long-term productivity improvements across the organization."
• "Looking ahead, we remain focused on disciplined execution, delivering 6% to 8% pro forma revenue growth in 2026, maintaining strong EBITDA margins, and creating long-term value for our shareholders."

Industry Context

StockSavvy.ai notes that InfuSystem's performance in Patient Services, particularly in Oncology and Wound Care, aligns with broader healthcare trends favoring outpatient and specialized care. The decline in Device Solutions, while impacting top-line revenue, appears to be a strategic move to improve profitability, a common consideration for companies optimizing service contracts.

Stakeholder Impact

• Shareholders: Reaffirmed guidance and improved profitability are positive indicators for shareholder value.
• Employees: Increased sales headcount and focus on efficiency may impact staffing and operational roles.
• Customers: Continued focus on patient services and durable medical equipment supports ongoing customer care.
• Suppliers: Growth in Wound Care and new supplier relationships indicate potential for increased business with suppliers.

Next Steps

• Continue focused execution on disciplined growth strategies.
• Maintain strong EBITDA margins.
• Create long-term value for shareholders.
• Continue to update annual guidance throughout the year.
• Participate in the conference call on August 4, 2026, to discuss results.

Key Dates

Recommendation

The company demonstrated solid operational execution with revenue growth and improved profitability, alongside reaffirmed guidance. However, the decline in the Device Solutions segment and increased net debt warrant a cautious 'hold' rating pending further clarity on the long-term impact of the contract restructuring and sustained growth across all segments.

Keywords

healthcare services, durable medical equipment, patient services, device solutions, oncology, wound care, lymphedema therapy, EBITDA